FDA hands BeOne, Taiho approvals for blood cancers
BeOne's gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.
Newsletters and Deep Dive digital magazine
BeOne's gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.
Medscape One (M1) is a sophisticated, AI-powered decision engine designed to redefine HCP engagement.
GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.
Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.
Marty Makary's position as FDA Commissioner is said to be in jeopardy, raising the threat of further chaos at the agency if he is ousted.
Editor's Picks
Newsletters and Deep Dive
digital magazine